How Does Tirzepatide Sustain Clinical Advantages in Real-World Settings?
How Does Tirzepatide Sustain Clinical Advantages in Real-World Settings? For patients and providers, the true test of a metabolic therapy lies in real-world performance—not just clinical trial results. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has answered this test resoundingly, capturing 57.9% of U.S. GLP-1 prescriptions by Q3 2025 (vs. 41.7% for semaglutide) . What enables […]
How Does Tirzepatide Sustain Clinical Advantages in Real-World Settings? Read More »
